Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that oral baricitinib treatment led to hair regrowth in patients with alopecia areata, as observed in two phase 3 trials.

This study found that activin affects both stromal cells and keratinocytes in skin morphogenesis and repair, with dose-dependent effects on keratinocytes demonstrated through transgenic mouse models.

This study found that ALRN-6924, a clinical-stage dual inhibitor, can selectively protect human scalp hair follicles from paclitaxel-induced toxicity and damage by inducing transient cell cycle arrest in healthy cells without affecting cancer cells, potentially reducing chemotherapy-induced alopecia.

ATP-sensitive potassium channels are important for hair growth.

In a real-world study, baricitinib was effective for scalp, eyebrow, and eyelash regrowth in patients with alopecia areata, showing clinically meaningful improvements as early as 3 months and increasing up to 12 months; satisfaction and perceived improvement were also high among participants.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

This study found that activating both PKM2 and Wnt/β-catenin signaling pathways significantly enhanced hair regrowth and hair follicle neogenesis in mice, suggesting a potential strategy for treating alopecia.

This study reported that the anti-γc antibody hC2 restored hair follicle homeostasis and suppressed hair loss in an AA-like mouse model by inhibiting autoreactive T-cell activity, suggesting that hC2 may offer a safer and more effective treatment for alopecia areata compared to current Jak inhibitors.

This study reports the synthesis and structural characterization of a novel dinuclear platinum(III) complex with potential antitumor and catalytic activity.

This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.

This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.

This study found that patients receiving active ritlecitinib doses reported greater satisfaction with hair growth compared to placebo, with high agreement observed between clinician evaluations of scalp hair improvement and patient satisfaction through week 48.

This study found that VEGFR-2 activation may play a role in hair follicle differentiation, proliferation, and apoptosis by co-expressing with several key proteins in normal human scalp skin.

In this study, researchers found that knocking down the transcription factor Csdc2 inhibited the proliferation of dermal papilla cells in cashmere goats, and identified its regulatory relationship with the gene Robo2, providing insights into the genetic mechanisms influencing cashmere fiber growth.

This source discusses a Phase 2 trial by Hu et al. that evaluated the efficacy of topical GT20029 compared to a placebo, though the abstract does not provide specific results.

In this study, crossing mice overexpressing antizyme with MEK mutants significantly delayed tumor development and reduced tumor frequency, likely by slowing cell growth in skin tumors.

This study found that TPA treatment transiently induces high levels of ODC in mouse epidermal cells, particularly around hair follicles, with localization reduced by retinoic acid or cycloheximide pretreatment.

This study found that the JAK1 inhibitors baricitinib and abrocitinib significantly reduced mechanical alloknesis in a murine model of atopic dermatitis, whereas the JAK2 inhibitor AZ960 had no effect.

This review discusses ongoing and past trials for novel acne treatments, focusing on topical agents with potential sebosuppressive, antimicrobial, or anti-inflammatory effects, without reporting new clinical results.

This study isolated and characterized two distinct types of caspase-like proteases from human epidermis, suggesting their involvement in keratinocyte differentiation and apoptosis processes.

In this research, the authors reported that long-term treatment with the JAK1/JAK2 inhibitor baricitinib effectively maintains hair regrowth in patients with severe alopecia areata and may gradually improve outcomes for partial responders over 104 weeks, without increasing side effect incidence.

ACTH promotes hair growth in mink, but α-MSH does not.

This study demonstrates that keratin K2 is crucial for proper keratinocyte structure and function in specific mouse skin areas, and its deficiency leads to cellular aggregates and skin abnormalities.

This study found that Akt2 and SGK3 are crucial for postnatal hair follicle development in mice, as their combined absence led to severe hair growth defects due to disrupted β-catenin-dependent transcriptional processes.

This article discusses arsenic trioxide as a treatment for refractory or relapsed acute promyelocytic leukemia, noting its effectiveness and manageable side effects.

HDAC1 is crucial for skin development and preventing tumors.

Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.